Cargando…
A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
Methylene dimethane sulphonate (MDMS), the first member of the homologous series of dimethane sulphonic acid esters, was administered to 19 patients with advanced epithelial ovarian cancer. All patients had received prior chemotherapy and in addition 3 had received prior radiotherapy. MDMS was given...
Autores principales: | Smith, D. B., Lind, M. J., Kaye, S. B., Newlands, E. S., Blackledge, G. R., Gibson, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246396/ https://www.ncbi.nlm.nih.gov/pubmed/3395557 |
Ejemplares similares
-
The nature of the resistance to methylene dimethane sulphonate in the Yoshida sarcoma.
por: Fox, B. W., et al.
Publicado: (1973) -
A Study of the Immunosuppressive Activity of Methylene Dimethane Sulphonate (MDMS) in Relation to its Effectiveness as an Anti-Tumour Agent
por: Fox, B. W., et al.
Publicado: (1972) -
Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Rubens, R. D., et al.
Publicado: (1991) -
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Carmichael, J., et al.
Publicado: (1990) -
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992)